Michael Raab, President & CEO of Ardelyx (ARDX 2.39%), reported a sale of 41,666 shares of Common Stock for a transaction value of approximately $243,000 on March 16, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 41,666 |
| Transaction value | $243,329 |
| Post-transaction shares (direct) | 1,816,448 |
| Post-transaction shares (indirect) | 25,364 |
| Post-transaction value (direct ownership) | $10.61 million |
Transaction and post-transaction values based on March 16, 2026 weighted average sale price of $5.84.
Key questions
- What was the structure of this transaction, and did it involve derivative securities?
This filing reflects an option exercise for 20,833 shares, immediately followed by the sale of 41,666 shares of common stock, highlighting the use of equity compensation as part of ongoing liquidity management. - How did this sale compare in size to Michael Raab's recent trading activity?
The sale matched the recent period's median transaction size of 41,666 shares (from October 2024 to March 2026), indicating a stable and routine cadence in line with Raab's 10b5-1 plan. - What is the impact on Raab's remaining ownership and capacity for future sales?
After this transaction, Raab holds 1,816,448 shares directly and 25,364 shares indirectly, and retains 374,168 stock options, providing continued exposure and capacity for future equity-based compensation events. - Is there any indication of acceleration, moderation, or deviation from historical trade sizes?
Trade sizes have remained consistent as available capacity has decreased, with this transaction representing 2.21% of Raab's total holdings, similar to several prior events, and reflecting routine portfolio management rather than a change in intent.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 3/16/26) | $5.84 |
| Market capitalization | $1.457 billion |
| Revenue (TTM) | $407.32 million |
| Net income (TTM) | ($61.6 million) |
* 1-year performance is calculated using March 16, 2026 as the reference date.
Company snapshot
- Offers proprietary medicines targeting gastrointestinal and cardiorenal diseases, with tenapanor as the lead product addressing irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease patients.
- Generates revenue through product sales and licensing agreements with international partners for drug commercialization.
- Serves healthcare providers and patients in the United States and international markets, focusing on those with gastrointestinal and kidney-related conditions.
Ardelyx is a biotechnology company specializing in the development and commercialization of innovative therapies for gastrointestinal and cardiorenal diseases. The company leverages a pipeline of proprietary compounds, with tenapanor as its flagship product, to address significant unmet needs in chronic kidney disease and related disorders. Strategic partnerships in key international markets and a focused approach to specialty therapeutics underpin Ardelyx's competitive positioning within the healthcare sector.
NASDAQ: ARDX
Key Data Points
What this transaction means for investors
Company insiders sell shares for all sorts of reasons. In this case, Ardelyx President and CEO Michael Raab sold a little more than 2% of his holdings as part of a 10b5-1 trading plan, which is a tool company insiders use to transact shares at predetermined amounts and times to avoid the perception of insider trading. Raab’s transaction also involved an option exercise for 20,833 shares, half of the total amount of shares Raab ultimately sold, at $0.99 a piece. He made a nearly identical trade the previous month.
Raab’s transaction was worth a little more than $240,000. Ardelyx stock was up 6.8% year over year on the date of the transaction, but it’s down 16.57% over the past five years. The biotech company recently appointed a new chief medical officer, Rajani Dinavahi, MD, who has more than 20 years of biotechnology and clinical leadership across immuno-oncology, autoimmune disease, metabolic conditions, nephrology, and transplantation. This hire may signal the future direction of the company in terms of clinical decisions and trials, something for investors to monitor.
Some of the company’s legal headwinds also appear tobe abating. In 2024, investors filed a class action lawsuit claiming the company’s executives misrepresented their intentions regarding applying for a Medicare program for the drug Xphozah. This March, investors dropped their appeal to revive the lawsuit.
According to Zacks, analysts have an average $16.10 price target on Ardelyx stock, suggesting potential upside of about 170%.
